Physician profile
Vikas Le-Kumar
NPI 1487159000
$1,649.03
in general payments reported to CMS, 2019-2025
25 companies · $1,533 in 2025
The $1,533 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $116 · 2025: $1,533.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,649.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,649.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $413.53 | 2024-2025 | Monjuvi, Zynyz, Zynyz |
| Exelixis INC. | $175.00 | 2025 | Cabometyx |
| Daiichi Sankyo INC. | $153.72 | 2025 | Enhertu |
| E.R. Squibb & Sons, L.L.C. | $137.18 | 2025 | Opdivo |
| Astrazeneca Pharmaceuticals Lp | $74.75 | 2025 | Calquence, Lynparza, Imfinzi |
| Merck Sharp & Dohme LLC | $68.89 | 2025 | Keytruda, Keytruda Qlex, Lynparza |
| Regeneron Healthcare Solutions, INC. | $63.00 | 2025 | Libtayo |
| Janssen Biotech, INC. | $59.94 | 2025 | Rybrevant, Darzalex, Talvey |
| Genzyme Corporation | $52.42 | 2025 | |
| Novartis Pharmaceuticals Corporation | $49.91 | 2025 | |
| Fennec Pharmaceuticals, INC. | $39.68 | 2025 | Fyarro |
| Glaxosmithkline, LLC. | $36.87 | 2025 | Ojjaara |
| Sumitomo Pharma America, INC. | $35.95 | 2025 | Orgovyx |
| Pharmaessentia USA Corporation | $29.34 | 2025 | Besremi |
| Caris Mpi, INC. | $28.85 | 2025 | Mi Cancer Seek |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $28.52 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $27.72 | 2025 | Onivyde |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.66 | 2025 | |
| Pharmacosmos Therapeutics INC. | $25.82 | 2025 | Monoferric |
| Gilead Sciences, INC. | $22.49 | 2025 | Trodelvy |
| Abbvie INC. | $22.17 | 2025 | |
| Agios Pharmaceuticals, INC. | $21.64 | 2025 | Pyrukynd |
| Aveo Pharmaceuticals, INC. | $20.55 | 2025 | |
| Spectrum Pharmaceuticals INC. | $19.91 | 2025 | Rolvedon |
| Puma Biotechnology, INC. | $14.52 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vikas Le-Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.